Código 300210 (Harmonized System 2012 by 6 digits)
2023: US$1.49B, Total Trade Exchange
2023: US$145M, International Sales
2023: US$1.34B, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process was US$1.49B.
In 2023, the states with the most international sales in Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process were Estado de México (US$85.4M), Baja California (US$37.7M), Ciudad de México (US$10.2M), and Jalisco (US$5.88M).
The states with the most international purchases in 2023 were Ciudad de México (US$1.19B), Estado de México (US$88.3M), Baja California (US$31M), Jalisco (US$16.1M), and Querétaro (US$2.6M).
In 2023, the main commercial destinations of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process were France (US$82.9M), United States (US$45.3M), Germany (US$3.69M), Austria (US$1.85M), and Italy (US$1.38M).
The main commercial origins of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process in 2023 were Switzerland (US$256M), Germany (US$250M), Puerto Rico (US$204M), United States (US$125M), and Ireland (US$100M).
In the global context, the main exporting countries of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process in 2022 were Germany (US$36.2B), Switzerland (US$34.4B), and United States (US$33.6B). In the same year, the main importing countries of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process were United States (US$57.1B), Germany (US$29.1B), and Switzerland (US$15B).
US$1.49B, Total Trade Exchange (2023)
In 2023, the total trade exchange of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process in Mexico (including international purchases and sales) was US$1.49B.
The visualizations show the net balance of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
November, 2024
In November 2024, international sales of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process were US$1.67M, while international purchases reached US$126M. The above results in a trade balance of -US$125M.
2024-Q4: US$2.44M, International Sales
The visualization shows the quarterly concentration of international sales of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process at state level.
In the fourth quarter of 2024, international sales were US$2.44M, being the states with the most sales Baja California (US$1.55M), Ciudad de México (US$669k), and Estado de México (US$216k).
Estado de México: US$85.4M, State with the Most International Sales (2023)
France: US$82.9M, Main commercial destination (2023)
In 2023, the states with the highest international sales in Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process were Estado de México (US$85.4M), Baja California (US$37.7M), Ciudad de México (US$10.2M), and Jalisco (US$5.88M).
In 2023, the countries with the most international purchases from Mexico were France (US$82.9M), United States (US$45.3M), Germany (US$3.69M), Austria (US$1.85M), and Italy (US$1.38M).
Ciudad de México: US$1.19B, State with the Most International Purchases (2023)
Switzerland: US$256M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process were Ciudad de México (US$1.19B), Estado de México (US$88.3M), Baja California (US$31M), Jalisco (US$16.1M), and Querétaro (US$2.6M).
The countries with the most international sales to Mexico in 2023 were Switzerland (US$256M), Germany (US$250M), Puerto Rico (US$204M), United States (US$125M), and Ireland (US$100M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process were Germany (US$36.2B), Switzerland (US$34.4B), and United States (US$33.6B). In the same year, the main importing countries for Other Fractions of Blood and Modified Immunological Products Obtained by Biotechnological Process were United States (US$57.1B), Germany (US$29.1B), and Switzerland (US$15B).